Nanoparticle Shows Preclinical Promise, Early Clinical Success
By Anette Breindl
Thursday, April 5, 2012
Scientists from BIND Biosciences Inc., with colleagues from both academia and industry, reported data Wednesday on a targeted therapy, BIND-014, that is able to specifically deliver chemotherapy docetaxel to prostate tumor cells and the vasculature of many different types of solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.